Literature DB >> 30767255

A 14-year review of a UK teledermatology service: experience of over 40 000 teleconsultations.

S H Mehrtens1, L Shall1, S M Halpern1.   

Abstract

BACKGROUND: There is a paucity of published evidence of established teledermatology (TD) services in the UK. An in-house TD service using store-and-forward technology was set up at a large regional dermatology department in 2004. AIM: To review the TD service at our centre, including teleconsultation numbers, coding of diagnoses and patient outcomes.
METHODS: Retrospective data were retrieved using the electronic patient database, from 31 July 2004 to 31 July 2018. More detailed information on patient outcomes was obtained from patient notes and histology records. A paper questionnaire was distributed to 100 patients to obtain patient feedback.
RESULTS: In total, 40 201 teleconsultations were made over 14 years, and 64% of cases were coded (n = 25 555), of which 77% were lesions. The most common coded lesions were benign naevus (25%), seborrhoeic keratosis (22%) and basal cell carcinoma (19%). Of the total number of cases, 50% were discharged to their general practitioner with advice, 34% were booked for surgery and 16% were booked for a face-to-face appointment. In the survey, 82% of patients surveyed felt that the service was 'good' or 'very good'. A detailed study between 1 January 2015 and 1 January 2016 showed that there were 383 patients (10%) with no diagnosis made following teleconsultation, suggesting diagnostic uncertainty. Reasons for this included lack of diagnostic features, possibility of malignancy and service factors. Within this cohort, there was 68% diagnostic concordance.
CONCLUSIONS: We have set up a successful TD service at a UK centre, which has prevented 16 282 face-to-face appointments over 14 years. Patient feedback has been very good. Review of cases with diagnostic uncertainty provides important information for service improvement and has not previously been documented.
© 2019 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2019        PMID: 30767255     DOI: 10.1111/ced.13928

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  6 in total

1.  French Teledermatologists: Activity and Motivations Prior to the COVID-19 Pandemic.

Authors:  Mathieu Bataille; Emmanuel Mahé; Valérie Dorizy-Vuong; Charbel Skayem; Anne Dompmartin; Marie-Aleth Richard; Jean Friedel; Florence Ottavy; Marie-Sophie Gautier; Priscille Carvalho; Tu Anh Duong
Journal:  Acta Derm Venereol       Date:  2021-05-26       Impact factor: 3.875

2.  Definitions, survey methods, and findings of patient satisfaction studies in teledermatology: a systematic review.

Authors:  Edward Hadeler; Howard Gitlow; Keyvan Nouri
Journal:  Arch Dermatol Res       Date:  2020-07-28       Impact factor: 3.017

3.  Teledermatology for acne during COVID-19: high patients' satisfaction in spite of the emergency.

Authors:  A Ruggiero; M Megna; M C Annunziata; L Abategiovanni; M Scalvenzi; A Tajani; G Fabbrocini; A Villani
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-13       Impact factor: 6.166

4.  Oculoplastic video-based telemedicine consultations: Covid-19 and beyond.

Authors:  Swan Kang; Peter B M Thomas; Dawn A Sim; Richard T Parker; Claire Daniel; Jimmy M Uddin
Journal:  Eye (Lond)       Date:  2020-05-12       Impact factor: 3.775

5.  Emergency Use and Efficacy of an Asynchronous Teledermatology System as a Novel Tool for Early Diagnosis of Skin Cancer during the First Wave of COVID-19 Pandemic.

Authors:  Antal Jobbágy; Norbert Kiss; Fanni Adél Meznerics; Klára Farkas; Dóra Plázár; Szabolcs Bozsányi; Luca Fésűs; Áron Bartha; Endre Szabó; Kende Lőrincz; Miklós Sárdy; Norbert Miklós Wikonkál; Péter Szoldán; András Bánvölgyi
Journal:  Int J Environ Res Public Health       Date:  2022-02-25       Impact factor: 4.614

Review 6.  International Teledermatology Review.

Authors:  Karen McKoy; Saul Halpern; Kudakwashe Mutyambizi
Journal:  Curr Dermatol Rep       Date:  2021-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.